7 Best Treatments for Chronic Cough in 2026

Chronic cough, defined as a cough lasting longer than eight weeks, affects about 5% of adults in the United States. That translates to more than 12 million people dealing with a condition that disrupts sleep, strains relationships, and can leave patients feeling dismissed after repeated visits with no clear answer.

For many, the cough persists even after treating common triggers like acid reflux, asthma, or postnasal drip. When that happens, the problem may not be in the lungs or throat at all. Emerging research points to cough hypersensitivity syndrome, a condition where the brain's cough reflex becomes sensitized and fires without a clear physical trigger. The treatment landscape for this kind of persistent cough has shifted significantly, with behavioral and neurological approaches now leading the way.

Key Takeaways

• Behavioral cough suppression therapy is now considered frontline treatment for refractory chronic cough, supported by a meta-analysis of 12 studies.
• Cough hypersensitivity syndrome involves neuroplastic changes in the brain's cough circuits, parallel to the central sensitization seen in chronic pain.
• Neuromodulators like gabapentin reduce cough frequency in adults with refractory chronic cough, per a meta-analysis of nine randomized trials.
• Combining behavioral therapy with a neuromodulator may produce better outcomes than either alone, based on randomized trial evidence.
• No medication has received FDA approval specifically for chronic cough in the U.S. as of September 2026.

1. Brain-Based Behavioral Cough Retraining

For adults whose chronic cough persists despite treating identifiable causes, behavioral cough suppression therapy (BCST) has become the frontline treatment approach. Rather than suppressing the cough with medication, BCST retrains the nervous system's response to stimuli that trigger unnecessary coughing.

What It Is

Chronic cough often involves neuroplastic changes in sensory neurons where the brain's cough circuits become hypersensitive. The cough reflex fires in response to stimuli like cold air, strong odors, or talking that wouldn't normally cause a cough. This parallels the central sensitization process seen in chronic pain, where the nervous system amplifies signals beyond what the original trigger warrants.

BCST addresses this sensitization through:

• Education about cough mechanisms and the hypersensitivity cycle
• Cough suppression strategies including controlled breathing and voluntary suppression techniques
• Psychoeducational counseling targeting anxiety and hypervigilance that amplify cough sensitivity
• Laryngeal irritant reduction and vocal hygiene practices

Lin Health applies the same brain-based behavioral principles to persistent symptoms. The program combines cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT), and somatic tracking into a coach-led, app-supported program designed to retrain the nervous system's sensitized response. Lin Health is covered by most major insurance plans in Colorado, Texas, Florida, California, and New York. Most enrolled patients pay nothing out of pocket, and wait times are short, often with a same-day callback after signup.

Why It Works

BCST improves cough-related quality of life in adults with refractory or unexplained chronic cough, with meaningful reductions in objective cough frequency. The 2026 ABEA expert consensus statement endorsed it as a low-risk cough intervention for adults with refractory chronic cough.

Internet-based delivery of behavioral cough therapy is also effective for refractory chronic cough, validating digitally delivered behavioral programs as a treatment option. Real-world data show meaningful response trajectories across different cough subtypes.

Who It's For

Adults with refractory chronic cough (persisting despite treatment of identifiable causes) or unexplained chronic cough (no cause found after thorough evaluation). Particularly relevant for people who notice their cough worsens with stress, strong scents, or temperature changes.

2. Ruling Out and Treating Underlying Triggers

Before exploring specialized treatments, a thorough medical evaluation is essential. Many chronic coughs have treatable underlying causes that, once addressed, resolve the cough entirely.

The Most Common Triggers

• Upper airway cough syndrome (UACS): Previously called postnasal drip. Treated with nasal corticosteroids, antihistamines, or saline irrigation.
• Asthma and eosinophilic bronchitis: Present in 24 to 32% of cases. Inhaled corticosteroids are the standard treatment.
• Gastroesophageal reflux (GERD): Acid and non-acid reflux irritate the vagus nerve, triggering cough. Proton pump inhibitors and dietary changes are first-line.
• ACE inhibitor medications: Affects 5 to 30% of patients taking these blood pressure medications. Switching drug classes typically resolves the cough within weeks.

The Evaluation Process

The standard workup begins with a chest X-ray and spirometry, followed by empiric treatment targeting the most likely cause based on symptoms. If the first treatment doesn't resolve the cough, the next most probable trigger is addressed. This stepwise approach resolves the cough in a substantial number of cases.

When Standard Treatment Isn't Enough

For a significant portion of chronic cough patients, evaluation either identifies no clear cause or treatment of identified causes doesn't fully resolve symptoms. These patients are classified as having refractory or unexplained chronic cough, and they benefit most from the behavioral, neuromodulatory, and combined approaches elsewhere on this list.

3. Neuromodulators

Neuromodulator medications target the sensitized nerve pathways driving the cough reflex. In adults with refractory chronic cough, these drugs reduce cough frequency significantly and improve quality of life.

What It Is

Gabapentin has the strongest evidence base. Prescribing guidelines recommend starting at 300 mg twice daily with a maximum of 1,800 mg per day. Gabapentin-specific analyses show meaningful reductions in cough frequency across multiple studies involving 536 participants.

Amitriptyline is typically started at 10 mg at bedtime with a maximum of 100 mg. It was the first neuromodulator evaluated with objective cough counts in a randomized trial, providing more rigorous data than earlier open-label studies.

Pregabalin has demonstrated benefit, especially when combined with behavioral therapy (see section 6).

Why It Works

Neuromodulators reduce nerve excitability in the cough reflex arc, dampening the peripheral and central sensitization that drives cough hypersensitivity. They act on calcium channels (gabapentin, pregabalin) or sodium channels and serotonin/norepinephrine pathways (amitriptyline) to lower the threshold at which the cough reflex fires.

The 2026 ABEA consensus notes, however, that side effects may limit use. Common issues include drowsiness, dizziness, and cognitive effects. These medications require careful dose titration and ongoing monitoring.

Who It's For

Adults whose chronic cough hasn't responded to treatment of underlying causes, particularly those with features of cough hypersensitivity like sensitivity to strong odors, cold air, or prolonged talking.

4. Breathing Exercises and Diaphragmatic Training

Targeted breathing techniques offer a low-risk complement to other chronic cough treatments, with emerging evidence for standalone benefit in specific subtypes.

What It Is

Several breathing strategies are used in cough management:

• Diaphragmatic breathing: Slow, deep breaths using the diaphragm rather than chest muscles, which strengthens the lower esophageal sphincter and reduces reflux-triggered cough
• Pursed-lip breathing: Used when a cough urge arises, to interrupt the reflex
• Controlled swallowing: Suppresses the cough cycle at the laryngeal level
• Relaxed throat breathing: Reduces the laryngeal tension that feeds cough sensitivity

Why It Works

Deep diaphragmatic breathing improves reflux-induced cough symptoms when combined with standard medication. Patients in the study also showed improvements in anxiety, sleep quality, and mood, suggesting the technique addresses both the mechanical and psychological dimensions of reflux-related cough.

Breathing strategies are also core components of BCST protocols, where they work by interrupting the cough reflex at the laryngeal level and reducing the hypervigilance that amplifies cough sensitivity.

Who It's For

Most adults with chronic cough, particularly those with a reflux component, anxiety-driven cough amplification, or laryngeal tension patterns. Breathing exercises carry minimal risk and can be practiced independently between clinical appointments.

5. Stress Management and Mental Health Support

Chronic cough and psychological health are closely connected. Addressing the mental health dimension is increasingly recognized as part of effective treatment.

What It Is

Stress management for chronic cough draws on several approaches:

• Cognitive behavioral therapy principles help patients recognize and change thought patterns (such as catastrophizing about the next coughing episode in a meeting) that amplify cough sensitivity
• Mindfulness-based techniques reduce the baseline stress and hypervigilance that feed cough hypersensitivity
• Sleep hygiene practices address the disrupted sleep that both results from and worsens chronic cough

Why It Works

Adults with chronic cough show higher anxiety, depression, and sleep disruption compared to those without chronic cough. The relationship runs both directions: chronic cough causes distress, and distress amplifies cough sensitivity through central nervous system pathways.

Mindfulness-based interventions improve anxiety and depression in adults with chronic pulmonary conditions, with benefits maintained at three-month follow-up. While this evidence covers chronic pulmonary diseases broadly rather than chronic cough specifically, the overlapping psychological mechanisms suggest relevance for cough patients dealing with stress.

Who It's For

Adults who notice cough worsening during emotional strain, who experience social avoidance due to coughing episodes, or who have co-occurring anxiety or depression amplifying symptoms.

6. Combined Behavioral and Medication Therapy

Behavioral therapy and neuromodulators together may work better than either approach alone, addressing both sides of the cough hypersensitivity pathway.

What It Is

A typical combined approach includes:

• A neuromodulator (gabapentin or pregabalin) titrated by a prescribing clinician
• Concurrent behavioral cough retraining, either with a speech-language pathologist or through a digital program
• Breathing exercises and cough suppression strategies practiced between sessions
• Regular reassessment of both cough frequency and quality-of-life measures

Why It Works

Pregabalin combined with speech pathology therapy produces significantly greater improvements in cough severity, quality of life, and cough sensitivity compared to speech pathology with placebo. The 2025 WAO-ARIA consensus on chronic cough endorses a multidisciplinary treatment approach.

The rationale: behavioral therapy addresses central sensitization (the brain's amplified cough response) while neuromodulators target peripheral nerve hypersensitivity, covering both ends of the cough pathway.

Who It's For

Adults with refractory chronic cough who have features of cough hypersensitivity and have not achieved sufficient relief from behavioral therapy or medication alone.

7. Emerging Pharmaceutical Treatments

The pharmaceutical pipeline for chronic cough has faced setbacks, but the underlying science continues to advance.

What It Is

P2X3 receptor antagonists target receptors on airway sensory nerves that play a role in heightened cough sensitivity. This drug class was widely expected to become the first approved medication specifically for chronic cough.

Gefapixant (Merck) was declined by the FDA in December 2023 for insufficient evidence of effectiveness. It remains available in Japan and parts of Europe, where clinical experience shows efficacy with taste disturbance as the primary side effect.

Camlipixant (GSK) showed promise as a next-generation option with fewer taste-related side effects. However, after mixed Phase III results where CALM-2 did not reach significance, GSK halted development in July 2026.

Superior laryngeal nerve blocks offer a procedural option for selected patients. The 2026 ABEA consensus describes them as safe and effective for patients who haven't responded to behavioral or pharmacological approaches.

What This Means Today

With no FDA-approved cough-specific medications available in the U.S. as of September 2026, behavioral and neuromodulatory approaches remain the most accessible and evidence-supported options. Research into new receptor targets and delivery methods continues.

How Lin Health May Help with Chronic Cough

The science behind chronic cough is converging on the same principle that drives Lin Health's approach to chronic pain: when symptoms persist beyond what the original trigger explains, the nervous system itself may be driving the problem.

Cough hypersensitivity syndrome involves neuroplastic changes in cough circuits where sensory neurons become sensitized and fire in response to stimuli that wouldn't normally trigger a cough. This mirrors the central sensitization mechanism that Lin Health addresses in chronic pain conditions, where the brain's danger signals keep firing after tissues have healed.

Lin Health's approach is based on findings from neuroplastic pain and symptom research, applying the same brain-first model to persistent symptoms. The program combines CBT, ACT, and somatic tracking, delivered through:

• Weekly one-on-one sessions with a trained recovery coach who specializes in persistent symptom conditions
• A structured app with learning modules and daily practice exercises
• Between-session support via chat with your coach
• A brain-based framework that complements medical care, not replaces it

Lin Health partners with Mayo Clinic and health systems including WellSpan and AdventHealth, and is covered by most major insurance plans in Colorado, Texas, Florida, California, and New York. Wait times are short, often with a same-day callback after signup.

If your chronic cough has persisted despite medical treatment, a behavioral approach rooted in neuroplastic science may be worth exploring. Most patients pay nothing out of pocket. Check your eligibility.

FAQ

What is chronic cough?

Chronic cough is a cough lasting longer than eight weeks in adults. It affects about 5% of adults in the U.S. and can stem from conditions like asthma, reflux, or postnasal drip. In many cases, no clear cause is identified after standard evaluation.

What is cough hypersensitivity syndrome?

Cough hypersensitivity syndrome occurs when the brain's cough reflex becomes sensitized through neuroplastic changes in sensory neurons. The cough circuits overreact to stimuli that wouldn't normally trigger coughing. It is increasingly recognized as the mechanism behind refractory and unexplained chronic cough.

Can behavioral therapy help chronic cough?

Behavioral cough suppression therapy is now considered frontline treatment for refractory chronic cough. A meta-analysis of 12 studies showed significant quality-of-life improvements, and internet-based delivery has been validated in a 2025 randomized trial.

What medications are used for chronic cough?

Neuromodulators including gabapentin, pregabalin, and amitriptyline are the primary pharmacological options for refractory chronic cough. Gabapentin is typically started at 300 mg twice daily. These require a prescription and monitoring for side effects like drowsiness and dizziness.

Are there FDA-approved drugs specifically for chronic cough?

No. As of September 2026, no medication has received FDA approval specifically for chronic cough in the United States. Gefapixant was rejected by the FDA in 2023, and camlipixant development was halted by GSK in 2026. Neuromodulators are prescribed off-label.

Does stress make chronic cough worse?

Research shows adults with chronic cough have higher anxiety and depression than those without chronic cough. Stress can amplify cough sensitivity through central nervous system pathways, which is why behavioral and stress management approaches are part of comprehensive treatment.

Is chronic cough treatment covered by insurance?

Most treatments for chronic cough, including physician visits, medications, and speech pathology, are covered by health insurance. Digital behavioral health programs like Lin Health are covered in select states including Colorado, Texas, Florida, California, and New York.

When should I see a doctor about a cough that won't stop?

See a clinician if your cough has lasted more than eight weeks, is getting worse, or comes with blood, unexplained weight loss, fever, or shortness of breath. Early evaluation helps rule out serious causes and connect you with appropriate treatment.

This article is for informational purposes and is not medical advice. Consult a qualified healthcare provider before starting, changing, or stopping any treatment for chronic cough. If you experience new or severe respiratory symptoms, seek prompt medical evaluation.